IGFL1 has been reported as a candidate target gene for AD, and it may be related to the abnormal activation of the immune response in AD patients, especially the activation of Th17 immunity, which is one of the key subtypes of the T-cell pathway [29]. Here, IGFL1 is linked to Alzheimer disease.